Lazard Asset Management LLC increased its position in shares of Mednax, Inc (NYSE:MD) by 30.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 295,449 shares of the company’s stock after purchasing an additional 68,365 shares during the quarter. Lazard Asset Management LLC owned 0.32% of Mednax worth $17,836,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MD. Pacer Advisors Inc. lifted its holdings in shares of Mednax by 8.1% in the second quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after acquiring an additional 145 shares during the last quarter. Commonwealth Bank of Australia lifted its holdings in shares of Mednax by 15.3% in the second quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after acquiring an additional 293 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of Mednax by 20.0% in the second quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock worth $181,000 after acquiring an additional 500 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of Mednax in the second quarter worth about $217,000. Finally, State of Alaska Department of Revenue lifted its holdings in shares of Mednax by 6.2% in the second quarter. State of Alaska Department of Revenue now owns 4,393 shares of the company’s stock worth $265,000 after acquiring an additional 257 shares during the last quarter.

Mednax, Inc (NYSE MD) opened at 42.00 on Friday. The company has a 50-day moving average of $43.21 and a 200-day moving average of $56.37. Mednax, Inc has a one year low of $40.78 and a one year high of $72.13. The company has a market cap of $3.87 billion, a price-to-earnings ratio of 13.38 and a beta of 0.40.

Mednax (NYSE:MD) last issued its quarterly earnings data on Friday, July 28th. The company reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The company had revenue of $843.00 million during the quarter, compared to analyst estimates of $849.49 million. During the same quarter in the previous year, the firm earned $1.03 earnings per share. Mednax’s revenue was up 9.2% on a year-over-year basis. Equities research analysts expect that Mednax, Inc will post $3.31 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/mednax-inc-md-position-raised-by-lazard-asset-management-llc/1580276.html.

A number of research analysts have recently commented on MD shares. ValuEngine cut shares of Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Friday, June 23rd. Robert W. Baird reissued a “hold” rating and issued a $47.00 target price on shares of Mednax in a report on Sunday, September 3rd. KeyCorp raised shares of Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price for the company in a report on Sunday, September 17th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $53.00 target price (up previously from $50.00) on shares of Mednax in a report on Thursday, July 6th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $58.89.

In other news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the completion of the transaction, the insider now owns 35,569 shares of the company’s stock, valued at $1,524,131.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.40% of the stock is currently owned by insiders.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.